Sorafenib and bevacizumab for recurrent metastatic hepatoblastoma: Stable radiographic disease with decreased AFP

Pediatric Blood and Cancer

Volumn 59, Issue 5, 2012, Pages 939-940

  Marsh, Anne M ^a   Lo, Louise ^b   Cohen, Ronald A ^a   Feusner, James H ^a  

^a CHILDREN S HOSPITAL OAKLAND   (United States)

^b CALIFORNIA PACIFIC MEDICAL CENTER   (United States)

Author keywords

Hepatoblastoma; New agents; Pediatric oncology

Indexed keywords

ALPHA FETOPROTEIN; BEVACIZUMAB; CARBOPLATIN; CISPLATIN; DOXORUBICIN; ERLOTINIB; ETOPOSIDE; FLUOROURACIL; IFOSFAMIDE; IRINOTECAN; PARACETAMOL; SORAFENIB; VINCRISTINE;

ABDOMINAL MASS; ARTICLE; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CANCER SURGERY; CASE REPORT; CHILD; COMPUTER ASSISTED TOMOGRAPHY; DRUG ERUPTION; DRUG MEGADOSE; DRUG TOLERABILITY; HEPATOBLASTOMA; HUMAN; LIVER RESECTION; LUNG LESION; LUNG METASTASIS; LUNG NODULE; MALE; MICROSCOPY; MULTIPLE CYCLE TREATMENT; PRESCHOOL CHILD; PRIORITY JOURNAL; RADIOGRAPHY; RECURRENT CANCER; TREATMENT DURATION; TREATMENT RESPONSE; TUMOR SEEDING; TUMOR VOLUME;

ALPHA-FETOPROTEINS; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; BENZENESULFONATES; CHILD, PRESCHOOL; HEPATOBLASTOMA; HUMANS; LIVER NEOPLASMS; MALE; NEOPLASM RECURRENCE, LOCAL; PYRIDINES;

EID: 84866159110     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.24171     Document Type: Article

References (20)

1. Maibach R, Roebuck D, Brugieres L, et al. Prognostic stratification for children with hepatoblastoma: The SIOPEL experience. Eur J Cancer 2012; http://dx.doi.org/10.1016/j.ejca.2011.12.011.
2. Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: A phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009; 10: 25-34.
3. Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007; 356: 125-134.
4. Escudier B, Pluzanska A, Koralewski P, et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: A randomised, double-blind phase III trial. Lancet 2007; 370: 2103-2111.
5. Garcia JA, Hutson TE, Elson P, et al. Sorafenib in patients with metastatic renal cell carcinoma refractory to either sunitinib or bevacizumab. Cancer 2010; 116: 5383-5390.
6. Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359: 378-390.
7. Wilhelm SM, Carter C, Tang L, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004; 64: 7099-7109.
8. Hurwitz HI, Fehrenbacher L, Hainsworth JD, et al. Bevacizumab in combination with fluorouracil and leucovorin: An active regimen for first-line metastatic colorectal cancer. J Clin Oncol 2005; 23: 3502-3508.
9. Miller K, Wang M, Gralow J, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007; 357: 2666-2676.
10. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006; 355: 2542-2550.
11. Azad NS, Posadas EM, Kwitkowski VE, et al. Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity. J Clin Oncol 2008; 26: 3709-3714.
12. Castellano DE, Capdevila J, Salazar R, et al. Sorafenib and bevacizumab combination targeted therapy in advanced neuroendocrine tumor: A phase II study of the Spanish Neuroendocrine Tumor Group (GETNE0801). J Clin Oncol 2011; 29: Abstr 4113.
13. Lee JM, Sarosy GA, Annunziata CM, et al. Combination therapy: Intermittent sorafenib with bevacizumab yields activity and decreased toxicity. Br J Cancer 2010; 102: 495-499.
14. Wich C, Agaimy A, Strobel D, et al. Sustained treatment response of metastatic hepatocellular carcinoma with bevacizumab and sorafenib. World J Gastroenterol 2010; 16: 3592-3596.
15. Glade Bender JL, Adamson PC, Reid JM, et al. Phase I trial and pharmacokinetic study of bevacizumab in pediatric patients with refractory solid tumors: A Children's Oncology Group Study. J Clin Oncol 2008; 26: 399-405.
16. Prokurat A, Kluge P, Kościesza A, et al. Transitional liver cell tumors (TLCT) in older children and adolescents: A novel group of aggressive hepatic tumors expressing beta-catenin. Med Pediatr Oncol 2002; 39: 510-518.
17. Lettieri JT, Dubowy R, Xia C, et al. Bioavailability of sorafenib tablets administered as a liquid suspension. J Clin Oncol 2009; 27: Abstr e14549.
18. Sanchez-Diaz PC, Chen TL, Meyers R, et al. Sorafenib, gamma-secretase inhibitor, and bortezomib as potential therapeutic agents for hepatoblastoma. J Clin Oncol 2010; 28: Abstr 9550.
19. Chen TT, Rakhelja D, Hung JY, et al. Establishment and characterization of a cancer cell line derived from an aggressive childhood liver tumor. Pediatr Blood Cancer 2009; 53: 1040-1047.
20. McCrudden KW, Hopkins B, Frischer J, et al. Anti-VEGF antibody in experimental hepatoblastoma: Suppression of tumor growth and altered angiogenesis. J Pediatr Surg 2003; 38: 308-314.